Concord Biotech Ltd

AI
Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Concord Biotech Ltd

₹ 1,268 -7.77%
28 Oct - close price
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.

Website BSE NSE
  • Market Cap ₹ 13,271 Cr.
  • Current Price ₹ 1,268
  • High / Low ₹ 1,615 / 987
  • Stock P/E 44.7
  • Book Value ₹ 199
  • Dividend Yield 0.30 %
  • ROCE 17.4 %
  • ROE 12.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Cons

  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
262 241 319 216 310 244 430 204 247 278 326 261 312
143 135 185 135 174 146 239 143 157 176 204 173 202
Operating Profit 119 106 134 81 137 98 190 61 91 102 122 87 110
OPM % 45% 44% 42% 38% 44% 40% 44% 30% 37% 37% 38% 33% 35%
8 8 11 10 10 15 9 14 13 7 16 13 10
Interest 1 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 13 14 14 13 13 13 15 18 18 19 19 18 18
Profit before tax 113 100 131 78 133 99 185 57 86 90 118 82 102
Tax % 25% 26% 26% 25% 26% 25% 23% 26% 26% 25% 24% 26% 26%
84 75 97 58 99 74 142 43 63 68 90 61 76
EPS in Rs 8.08 7.13 9.29 5.57 9.43 7.08 13.57 4.07 6.01 6.48 8.60 5.85 7.24
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
239 276 340 436 512 617 713 853 1,017 1,200 1,055 1,177
133 145 212 256 308 289 439 509 585 693 678 755
Operating Profit 105 131 127 180 205 328 274 344 432 507 377 422
OPM % 44% 48% 37% 41% 40% 53% 38% 40% 42% 42% 36% 36%
11 8 36 17 31 14 23 35 34 44 49 46
Interest 1 0 1 1 1 1 6 5 3 1 1 0
Depreciation 10 10 18 19 21 28 50 54 54 54 74 75
Profit before tax 106 129 144 178 213 313 241 320 409 496 351 393
Tax % 34% 33% 30% 33% 21% 25% 26% 26% 26% 25% 25%
70 87 100 118 169 235 179 238 305 373 263 295
EPS in Rs 6.93 8.61 9.61 11.32 16.15 22.50 17.07 22.76 29.13 35.65 25.17 28.17
Dividend Payout % 22% 25% 0% 21% 22% 0% 3% 30% 30% 25% 30%
Compounded Sales Growth
10 Years: 14%
5 Years: 11%
3 Years: 7%
TTM: 5%
Compounded Profit Growth
10 Years: 11%
5 Years: 1%
3 Years: 1%
TTM: -8%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 3%
1 Year: -13%
Return on Equity
10 Years: %
5 Years: 18%
3 Years: 18%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 9 9 10 10 10 10 10 10 10 10 10 10
Reserves 268 329 585 673 761 990 1,098 1,282 1,515 1,802 2,009 2,076
35 36 22 9 52 89 62 32 10 3 1 1
55 74 69 71 118 94 144 191 164 219 216 252
Total Liabilities 367 448 685 763 941 1,183 1,313 1,515 1,699 2,034 2,237 2,339
104 110 189 230 240 546 573 593 575 795 786 764
CWIP 19 70 3 19 141 18 74 173 211 51 79 112
Investments 42 43 151 229 199 142 74 138 244 335 488 535
202 225 343 285 361 477 592 611 668 854 883 928
Total Assets 367 448 685 763 941 1,183 1,313 1,515 1,699 2,034 2,237 2,339

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
79 155 167 207 246 265 245 264
-42 -114 -195 -112 -158 -155 -160 -142
-37 -43 31 -100 -85 -99 -99 -115
Net Cash Flow 0 -1 3 -4 3 12 -14 7
Free Cash Flow 79 -1 -37 52 101 180 134 169
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 101% 100% 74% 98% 92% 85% 70% 96%

Ratios

Standalone / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 165 182 236 133 131 105 119 117 125 159 159
Inventory Days 276 321 381 310 312 503 434 430 331 286 483
Days Payable 108 129 210 112 201 152 185 190 150 135 150
Cash Conversion Cycle 334 374 407 331 242 456 368 357 306 310 492
Working Capital Days 195 209 275 177 159 177 163 153 166 193 231
ROCE % 37% 25% 25% 32% 21% 26% 28% 28% 17%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
API Share of Revenue
% of total revenue

Log in to view insights

Please log in to see hidden values.

Login
Capacity Utilization - Unit 1 (API, Dholka)
%
Domestic Share of Revenue
% of total revenue
R&D Spends
Rs Crores
Top 10 Customer Concentration
% of total revenue
New Customer Additions
count
Capacity Utilization - Unit 3 (API, Limbasi)
%
API Drug Master Files (DMFs) Filed
count (cumulative)

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.09%
7.00% 6.49% 7.11% 8.10% 8.33% 9.35% 9.10% 8.03% 7.58% 7.79% 7.53% 7.28%
8.40% 8.41% 10.35% 9.89% 9.65% 9.16% 8.85% 9.55% 9.58% 9.22% 9.37% 10.95%
40.52% 41.03% 38.46% 37.95% 37.93% 37.41% 37.94% 38.32% 38.75% 38.90% 39.04% 37.68%
No. of Shareholders 87,48683,29680,73784,29882,00481,21982,04582,65081,81582,24983,32588,365

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls